Mainz BioMed N.V.
A molecular genetics diagnostics company developing tests for early cancer detection.
MYNZ | F
Overview
Corporate Details
- ISIN(s):
- NL0015000LC2 (+3 more)
- LEI:
- 894500XWJE7LIJNYQ547
- Country:
- Germany
- Address:
- Robert-Koch-Strasse 50, 55129 Mainz
- Website:
- https://mainzbiomed.com/
- Sector:
- Manufacturing
Description
Mainz BioMed N.V. is a molecular genetics diagnostics company that develops market-ready solutions for the early detection of life-threatening conditions, with a primary focus on cancer. The company's flagship product is ColoAlert, a user-friendly, non-invasive, at-home diagnostic test for colorectal cancer. This test combines stool-based DNA analysis with fecal immunochemical testing (FIT) to identify cancer indicators. In addition to its commercialized colorectal cancer screening test, Mainz BioMed is actively developing a portfolio of new diagnostic solutions, including genetic testing methods for pancreatic cancer, to transform cancer detection into prevention.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-02 14:01 |
DoctorBox Adds Mainz Biomeds ColoAlert to Its Portfolio
|
English | 12.0 KB | ||
| 2025-11-18 14:01 |
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South…
|
English | 12.4 KB | ||
| 2025-11-12 14:01 |
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
|
English | 11.6 KB | ||
| 2025-11-10 14:01 |
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Worki…
|
English | 11.6 KB | ||
| 2025-10-15 15:01 |
Mainz Biomed to Attend 2025 Maxim Growth Summit
|
English | 10.2 KB | ||
| 2025-10-08 15:00 |
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel …
|
English | 12.2 KB | ||
| 2025-09-30 14:01 |
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Sc…
|
English | 12.1 KB | ||
| 2025-09-23 14:01 |
Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland
|
English | 11.5 KB | ||
| 2025-09-02 14:01 |
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
|
English | 11.2 KB | ||
| 2025-08-13 14:01 |
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert
|
English | 11.6 KB | ||
| 2025-07-23 14:01 |
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for…
|
English | 11.2 KB | ||
| 2025-07-15 14:01 |
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colore…
|
English | 15.5 KB | ||
| 2025-06-25 14:01 |
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Scr…
|
English | 11.1 KB |
Automate Your Workflow. Get a real-time feed of all Mainz BioMed N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mainz BioMed N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mainz BioMed N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
